Abbvie

AbbVie, a US-based Pharmaceutical Preparation Manufacturing company, reported its Scope 1 emissions as 304,649,000 kg CO2e and its market-based Scope 2 emissions as 76,201,000 kg CO2e in 2025. This compares to 2024 figures of 300,072,000 kg CO2e for Scope 1 and 122,287,000 kg CO2e for market-based Scope 2. In 2023, Scope 1 emissions were 328,259,000 kg CO2e, and market-based Scope 2 emissions were 131,232,000 kg CO2e. The company has not disclosed Scope 3 emissions data.

AbbVie has set several climate commitments. It aims to achieve net-zero emissions by 2050 for Scope 1 and Scope 2. The company also commits to reduce absolute Scope 1 and Scope 2 GHG emissions by 42.0% by 2030, from a 2021 base year. This target is validated by the Science Based Targets initiative (SBTi) as consistent with keeping warming to 1.5°C. Additionally, AbbVie plans to increase active sourcing of renewable electricity from 29.5% in 2021 to 100.0% by 2030 and commits that 79.1% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027.

Earlier targets include a 25% reduction in absolute Scope 1 and Scope 2 (market-based) GHG emissions by 2025 against a 2015 baseline, and a long-term goal of a 50% reduction by 2035 from the same 2015 baseline. Furthermore, AbbVie aims for at least a 42% reduction of Scope 1 emissions from its fleet by 2030 through the electrification of sales fleet vehicles.